MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to represent a sustainable long-term revenue generator.

Moderna , Inc. (NASDAQ:MRNA) shares surged 14% following remarks by Oracle (NYSE:ORCL) Chairman Larry Ellison on the transformative potential of artificial intelligence (AI) in healthcare, particularly in early cancer detection and the development of personalized vaccines.